Charles Schwab’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.63M | Buy |
69,358
+3,918
| +6% | +$357K | ﹤0.01% | 2341 |
|
|
2026
Q1 | $6.3M | Sell |
65,440
-2,780
| -4% | -$278K | ﹤0.01% | 2305 |
|
|
2025
Q4 | $6.64M | Sell |
68,220
-268
| -0.4% | -$23K | ﹤0.01% | 2320 |
|
|
2025
Q3 | $4.87M | Buy |
68,488
+1,202
| +2% | +$80.1K | ﹤0.01% | 2451 |
|
|
2025
Q2 | $4.02M | Buy |
67,286
+2,215
| +3% | +$121K | ﹤0.01% | 2421 |
|
|
2025
Q1 | $3.41M | Sell |
65,071
-770
| -1% | -$43.3K | ﹤0.01% | 2427 |
|
|
2024
Q4 | $3.62M | Sell |
65,841
-791
| -1% | -$41.6K | ﹤0.01% | 2490 |
|
|
2024
Q3 | $3.35M | Buy |
66,632
+43,635
| +190% | +$2.01M | ﹤0.01% | 2549 |
|
|
2024
Q2 | $1.01M | Buy |
22,997
+3,224
| +16% | +$137K | ﹤0.01% | 2934 |
|
|
2024
Q1 | $870K | Sell |
19,773
-710
| -3% | -$31.4K | ﹤0.01% | 2839 |
|
|
2023
Q4 | $972K | Hold |
20,483
| – | – | ﹤0.01% | 2846 |
|
|
2023
Q3 | $909K | Buy |
20,483
+521
| +3% | +$24.2K | ﹤0.01% | 2828 |
|
|
2023
Q2 | $953K | Buy |
19,962
+613
| +3% | +$27.6K | ﹤0.01% | 2790 |
|
|
2023
Q1 | $761K | Hold |
19,349
| – | – | ﹤0.01% | 2823 |
|
|
2022
Q4 | $547K | Buy |
19,349
+484
| +3% | +$13.8K | ﹤0.01% | 2976 |
|
|
2022
Q3 | $568K | Sell |
18,865
-70
| -0.4% | -$2.44K | ﹤0.01% | 2967 |
|
|
2022
Q2 | $643K | Buy |
18,935
+1,382
| +8% | +$49.5K | ﹤0.01% | 2967 |
|
|
2022
Q1 | $788K | Buy |
17,553
+690
| +4% | +$31.9K | ﹤0.01% | 2950 |
|
|
2021
Q4 | $780K | Hold |
16,863
| – | – | ﹤0.01% | 3004 |
|
|
2021
Q3 | $567K | Hold |
16,863
| – | – | ﹤0.01% | 3103 |
|
|
2021
Q2 | $496K | Buy |
16,863
+1,140
| +7% | +$31.4K | ﹤0.01% | 3170 |
|
|
2021
Q1 | $406K | Buy |
15,723
+1,944
| +14% | +$46.4K | ﹤0.01% | 3146 |
|
|
2020
Q4 | $315K | Hold |
13,779
| – | – | ﹤0.01% | 3143 |
|
|
2020
Q3 | $295K | Hold |
13,779
| – | – | ﹤0.01% | 3031 |
|
|
2020
Q2 | $320K | Buy |
13,779
+3,055
| +28% | +$65.6K | ﹤0.01% | 3010 |
|
|
2020
Q1 | $229K | Sell |
10,724
-661
| -6% | -$15.7K | ﹤0.01% | 2978 |
|
|
2019
Q4 | $267K | Buy |
11,385
+885
| +8% | +$20.7K | ﹤0.01% | 2997 |
|
|
2019
Q3 | $221K | Hold |
10,500
| – | – | ﹤0.01% | 3030 |
|
|
2019
Q2 | $215K | Buy |
10,500
+2,666
| +34% | +$62.8K | ﹤0.01% | 3078 |
|
|
2019
Q1 | $221K | Buy |
+7,834
| New | +$205K | ﹤0.01% | 3006 |
|
|
2018
Q4 | – | Sell |
-7,834
| Closed | -$292K | – | 3150 |
|
|
2018
Q3 | $292K | Buy |
+7,834
| New | +$211K | ﹤0.01% | 3008 |
|
|
2016
Q3 | – | Sell |
-13,300
| Closed | -$290K | – | 3043 |
|
|
2016
Q2 | $290K | Buy |
+13,300
| New | +$239K | ﹤0.01% | 2797 |
|
Other funds holding IRMD
CCM
NTCM
Charles Schwab's IRMD Position: Q2 2026 in Review
Charles Schwab increased its iRadimed (IRMD) stake by 6% in Q2 2026, buying an estimated $357K and bringing the position to 69,358 shares worth $6.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2341.
Charles Schwab first reported a position in IRMD in Q2 2016 and has held it in 32 quarters since. The position peaked at $6.64M in Q4 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.
- Charles Schwab held 69,358 shares of iRadimed worth $6.63M as of Q2 2026.
- Charles Schwab bought 3,918 iRadimed shares in Q2 2026, an estimated $357K.
- iRadimed made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2341 holding.
- Charles Schwab first reported a position in iRadimed in Q2 2016 and has held it in 32 quarters since.
- Charles Schwab's iRadimed position peaked at $6.64M in Q4 2025.
- 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.